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http://dx.doi.org/10.1016/j.stemcr.2016.07.002SUMMARYIn human-to-mouse xenograft models, reconstitution of human hematopoiesis is usually B-lymphoid dominant. Here we show that
the introduction of homozygous KitWv mutations into C57BL/6.Rag2nullIl2rgnull mice with NOD-Sirpa (BRGS) strongly promoted
human multi-lineage reconstitution. After xenotransplantation of human CD34+CD38 cord blood cells, these newly generated
C57BL/6.Rag2nullIl2rgnullNOD-Sirpa KitWv/Wv (BRGSKWv/Wv) mice showed significantly higher levels of human cell chimerism and
long-term multi-lineage reconstitution compared with BRGS mice. Strikingly, this mouse displayed a robust reconstitution of human
erythropoiesis and thrombopoiesis with terminal maturation in the bone marrow. Furthermore, depletion of host macrophages by
clodronate administration resulted in the presence of human erythrocytes and platelets in the circulation. Thus, attenuation of mouse
KIT signaling greatly enhances the multi-lineage differentiation of human hematopoietic stem and progenitor cells (HSPCs) in mouse
bone marrow, presumably by outcompeting mouse HSPCs to occupy suitable microenvironments. The BRGSKWv/Wv mouse model is a
useful tool to study human multi-lineage hematopoiesis.INTRODUCTION
Immunodeficient mice are widely used as hosts for xenoge-
neic transplantation to studyhumanhematopoiesis in vivo
(Doulatov et al., 2012; Goyama et al., 2015; Ishikawa, 2013;
Rongvaux et al., 2013; Shultz et al., 2012). Elimination
of the mouse lymphoid system, including T, B, and natural
killer (NK) cells, is necessary to prevent human graft rejec-
tion. Thus, mice with the scid mutation (Greiner et al.,
1998;McCune et al., 1988; Shultz et al., 1995) or those lack-
ing recombination activating gene 1 or 2 (Rag1 or Rag2)
(Goldman et al., 1998; Shultz et al., 2000, 2003) have
been used. In addition, these mice also had mutations in
the interleukin-2 (IL-2) receptor common g-chain subunit
(Il2rg) gene (Ishikawa et al., 2005; Ito et al., 2002; Shultz
et al., 2005). Previous studies reported that a non-obese dia-
betic (NOD) or BALB/c genetic background facilitates hu-
man hematopoietic stem cell (HSC) engraftment (Brehm
et al., 2010). Therefore, these strains with complete
lymphoid depletion, such as NOD-scid Il2rgnull (NSG/
NOG) (Ito et al., 2002; Shultz et al., 2005), NOD.Rag1null
Il2rgnull (NOD-RG) (Pearson et al., 2008), and BALB/
c.Rag1/2nullIl2rgnull (BALB-RG) (Brehm et al., 2010; Traggiai
et al., 2004) mice, have been commonly used for recent
xenotransplantation experiments.
We found that the strain-specific genetic determinant of
human HSC engraftment was a polymorphism in the
signal-regulatory protein a (Sirpa) gene (Iwamoto et al.,
2014; Takenaka et al., 2007; Yamauchi et al., 2013). SIRPAStem Cell Rep
This is an open access article under the Cis expressed on the surface of macrophages and binds to its
ligand, CD47, which is ubiquitously expressed (Matozaki
et al., 2009). This binding activates inhibitory signals for
phagocytosis of CD47-expressing cells, termed the ‘‘don’t
eatme signal’’ (Jaiswal et al., 2009;Kuriyamaet al., 2012;Ma-
jeti et al., 2009; Oldenborg et al., 2000). In the setting of hu-
man-to-mousexenotransplantation, this inhibitory signal is
necessary to prevent engulfment of human graft cells by
host macrophages. Although the binding of SIRPA and
CD47 is species specific (Subramanian et al., 2006), NOD
and BALB/c mouse strains contain unique SIRPA immuno-
globulin (Ig) domains that cross-react with human CD47
(Iwamoto et al., 2014; Takenaka et al., 2007). With regard
tohumanCD47,NOD-SIRPAhas the strongest affinitywhile
BALB/c-SIRPA has an intermediate affinity (Iwamoto et al.,
2014), and it is not recognized by C57BL/6-SIRPA. Based
on these data, we developed a C57BL/6.Rag2nullIl2rgnull
mouse line harboring NOD-Sirpa (BRGS) (Yamauchi et al.,
2013). The efficiency of human cell engraftment in BRGS
mice is significantly greater than in NOD-RGmice. Because
BRGS mice do not possess a number of other NOD-specific
abnormalities, including complement 5 deficiency (Yamau-
chi et al., 2013), they are also useful for testing the com-
plement-dependent cytotoxic activity of antibodies in vivo
(Kikushige and Miyamoto, 2013). Thus, the BRGS mouse
line is one of themost efficient and convenient immunode-
ficient mouse strains for xenotransplantation.
However, in these models, human hematopoietic recon-
stitution is usually B-lymphoiddominant, and engraftmentorts j Vol. 7 j 425–438 j September 13, 2016 j ª 2016 The Authors. 425
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of human myeloid, erythroid, and megakaryocyte lineages
is limited (Doulatov et al., 2012; Ito et al., 2012; Rongvaux
et al., 2013; Yamauchi et al., 2013). This skewed reconsti-
tution could be due to the poor cross-reactivity of mouse
cytokines with their corresponding human cytokine recep-
tors (Manz, 2007). Indeed, BALB-RG mice carrying the
human thrombopoietin gene displayed enhanced hu-
man cell engraftment and myelomonocytic differentiation
(Rongvaux et al., 2011). The development of MITRG mice
by further humanization of BALB-RG mice, generated by
knocking in four human cytokines, namely macrophage
colony-stimulating factor, granulocyte/macrophage col-
ony-stimulating factor, IL-3, and thrombopoietin, has
facilitated the functional development of human macro-
phages, monocytes, and NK cells (Rongvaux et al., 2014).
The receptor tyrosine kinase KIT, which is expressed on he-
matopoietic stemandprogenitor cells (HSPCs), functions as
an essential regulator of the interaction between these cells
and their niches by binding to its ligand, stem cell factor
(SCF) (Czechowicz et al., 2007; Lyman and Jacobsen,
1998). Transgenic expression of membrane-bound human
SCF in NSGmice resulted in improved human cell engraft-
ment andmyeloiddifferentiation (Takagi et al., 2012).How-
ever, even in these models, only low levels of human
erythroid and megakaryocyte reconstitution were present.
For successful full-lineage engraftment, human HSPCs
may need to find suitable niches within the mouse bone
marrow. It was shown that immunodeficient mice with
loss-of-function Kit mutations (Waskow et al., 2009) or
those treated with a neutralizing anti-mouse KIT antibody
(Czechowicz et al., 2007) accepted donor mouse HSCs
without irradiation preconditioning that may be critical
for the depletion of host HSCs to open their niches. Recent
studies also showed that irradiation preconditioning was
not required for human HSPCs to engraft in BALB-RG or
NSG mice with KitW41 or KitWv mutations (Cosgun et al.,
2014; McIntosh et al., 2015). These studies suggest that
impaired KIT signaling renders mouse HSCs uncompetitive
in occupying putative niches, therefore allowing human
HSCs to access to mouse HSC niches and to expand in
the mouse bone marrow.
In the present study, we established a BRGS strain with
loss-of-function KitWv mutation (BRGSK). The homozy-
gous KitWv BRGS mouse (BRGSKWv/Wv) is viable. In addi-
tion, it supports human hematopoietic reconstitution
more efficiently after transplantation of human cord blood
(CB) cells when comparedwith BRGSmice. In BRGSKWv/Wv
mice, human myeloid reconstitution was dramatically
improved and all types of myeloid cells were observed.
More strikingly, abundant human erythroid and megakar-
yocyte cell lineages developed in BRGSKWv/Wvmouse bone
marrow. This BRGSK mouse line is a useful tool for in vivo
studies of human multi-lineage hematopoiesis.426 Stem Cell Reports j Vol. 7 j 425–438 j September 13, 2016RESULTS
Establishment and Characterization of the BRGSK
Mouse Line
The heterozygous KitWv BRGSmouse line (BRGSKWv/+) was
established by introducing theKitWv allele of theC57BL/6J-
KitWv mouse into the BRGS mouse (Yamauchi et al., 2013).
Becausemice homozygous forKitWv are sterile (Nocka et al.,
1990; Sharma et al., 2007), the BRGSKWv/Wvmouse was ob-
tained by mating BRGSKWv/+ pairs.
BRGSKWv/Wv mice had a white coat color (Figure 1A)
and developed severe macrocytic anemia with a signifi-
cant decrease in erythrocyte count (Figure 1B), as seen
in homozygous C57BL/6J-KitWv mice (Nocka et al.,
1990; Sharma et al., 2007). The number of leukocytes
and platelets was not significantly different to that in
BRGS mice. BRGSKWv/+ and BRGSKWv/Wv mice had a short
median life span of 58 weeks and 35 weeks, respectively
(Figure 1C). However, serial analysis of BRGSK mice re-
vealed that aging did not exacerbate macrocytic anemia
(data not shown). Their bone marrow cellularity and the
number of HSCs and megakaryocyte-erythrocyte pro-
genitors (MEPs) were similar to those in BRGS mice; in
addition, they did not decline with age (Figure 1D). These
results suggest that BRGSKWv/+ and BRGSKWv/Wv mice do
not develop bone marrow failure until at least 30 weeks
after birth.
BRGSKMice Have Improved Human Cell Engraftment
Efficiency Compared with BRGS Mice
Six- to 8-week-old BRGS, BRGSKWv/+, and BRGSKWv/Wv
mice were sublethally irradiated, and injected with 3.5–
5 3 103 human lineage-depleted (Lin) CD34+CD38 CB
cells. Injections were administered into the right femur.
We used intrafemoral injections because they provided
higher engraftment levels than intravenous injections in
the xenotransplantation model (McKenzie et al., 2005; Ya-
mauchi et al., 2013). At 8–12 weeks after transplantation,
both BRGSKWv/+ and BRGSKWv/Wv mice displayed higher
levels of human hematopoietic reconstitution in the
bonemarrow compared with BRGS control mice. In the in-
jected right femur, the average frequency of human CD45+
cells in BRGSKWv/+ and BRGSKWv/Wv mice was 92.2% and
97.8%, respectively, and was 80.1% in BRGS mice (Fig-
ure 2A, left panel). We previously showed that human
cell chimerism in male NOD-RG and BRGS recipients was
lower than that in female recipients (Yamauchi et al.,
2013). However, under the same transplantation protocol,
both male and female BRGSKWv/Wv mice showed a similar
excellent reconstitution (Figure S2). It was also reported
that human cell chimerism in the non-injected side was
very low (McDermott et al., 2010;McKenzie et al., 2005; Ya-
hata et al., 2003). Interestingly, even in the non-injected
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Figure 1. BRGSKWv/Wv Mice Develop Severe Macrocytic Anemia
(A) The appearance of the BRGSKWv/Wv mouse at 8 weeks of age.
(B) Frequencies of blood leukocytes, erythrocytes, and platelets, and the levels of hemoglobin, hematocrit, and mean corpuscular volume
(MCV) in 8-week-old BRGS, BRGSKWv/+, and BRGSKWv/Wv mice (n = 9 mice per strain). All BRGSKWv/Wv mice had macrocytic anemia. The
numbers and horizontal bars indicate mean values in each strain. **p < 0.01, ***p < 0.001.
(C) Kaplan-Meier survival curves for BRGS (n = 12), BRGSKWv/+ (n = 30), and BRGSKWv/Wv (n = 10) mice. Log-rank test: p < 0.0001.
(D) Changes in the absolute number of femoral bone marrow cells and LinSCA-1+c-KIT+ (LSK) cells, and in the frequency of MEPs in BRGS,
BRGSKWv/+, and BRGSKWv/Wv mice (n = 4 mice per group). Error bars indicate SEM. *p < 0.05, **p < 0.01. LSK, LinSCA-1c-KIT+.left femur, the average human CD45+ cell chimerism
reached 82.0% and 97.4% in BRGSKWv/+ and BRGSKWv/Wv
mice, respectively, compared with 56.7% in BRGS mice
(Figure 2B, left panel). These data clearly show that the
introduction of the KitWv allele into the BRGS strain has a
significant impact on the level of human cell reconstitu-
tion, and that it also accelerates the homing of human
HSCs to bone marrow niches via the circulation.
We then analyzed the long-term repopulating activity of
humanHSCs at 20–24 weeks after transplantation, because
it was reported that constant reconstitution (greater than
20 weeks) in xenogeneic hosts reflects the successful self-
renewal of human HSCs in mouse bone marrow (Notta
et al., 2011). BRGSKWv/Wv mice maintained a high level
of human cell reconstitution (average = 86.4%) in the rightfemur, whereas human cell chimerism significantly
declined in both BRGS and BRGSKWv/+ mice (average =
38.9% and 54.6%, respectively) (Figure 2A, right panel).
In the non-injected left femur, only BRGSKWv/Wv mice
maintained considerable levels of human cell chime-
rism (average = 53.8%) (Figure 2B, right panel). Further-
more, when we purified 106 human CD45+ cells from cry-
opreserved bone marrow cells of primary BRGSKWv/Wv
recipients and transplanted them into irradiated adult
BRGS mice, multi-lineage engraftment of human hemato-
poietic cells was observed in 7 of 15 secondary recipients
at 8 weeks after the secondary transplantation (Figure 2C).
Collectively, the introduction of homozygous KitWv muta-
tions into the BRGS strain is critical for the long-termmain-
tenance and self-renewal of human HSCs.Stem Cell Reports j Vol. 7 j 425–438 j September 13, 2016 427
AB
C Figure 2. Efficient Long-Term Human
Hematopoietic Reconstitution and Self-
Renewal of Human HSCs in BRGSKWv/Wv
Mice
(A and B) Human cell chimerism in the bone
marrow of the right femur injected with 3.5–
5 3 103 human CD34+CD38 CB cells (A),
and of the non-injected left femur (B) at
8–12 weeks and 20–24 weeks after trans-
plantation. Open and closed symbols repre-
sent females and males, respectively (n =
5–23 mice per strain). The numbers and
horizontal bars indicate mean values from
four independent experiments in each strain.
*p < 0.05, **p < 0.01, ***p < 0.001.
(C) Human cell chimerism in secondary BRGS
recipients injected with human CD45+ cells
purified from cryopreserved bone marrow
cells of primary BRGSKWv/Wv recipients. At
8 weeks after the secondary transplantation,
7 of 15 secondary recipients reconstituted
human hematopoiesis in the bone marrow.
The number and horizontal bar indicate mean
value from four independent experiments.
See also Figures S1 and S2.BRGSKWv/Wv Mice Efficiently Reconstitute All Human
Myeloid Lineages
Figure 3 shows the lineage analysis of human CD45+ cells
reconstituted in the injected right femur. In BRGS and
BRGSKWv/+ mice, greater than 90% of engrafted human
CD45+ cells were CD19+ B cells, and only up to 6% of
CD33+ myeloid cells were observed at 8–12 weeks after
transplantation (Figure 3B, left panel). In contrast,
BRGSKWv/Wv mice had an average of 65% CD19+ B cells,
resulting from a high level of myeloid reconstitution.
CD33+ myeloid cells reached an average of 32.5% within
the total human CD45+ population, and reached 57.3%
at 20–24 weeks after transplantation (Figure 3B, right
panel). NK cell reconstitution was also significantly
improved in BRGSKWv/Wv mice. The enhanced multi-
lineage reconstitution in BRGSKWv/Wv recipients was
also seen in the non-injected left femur (Figure S3).
Reconstituted B cells were polyclonal and expressed
IgM with either the Igk or Igl light chain, and human
T cell maturation was achieved in the BRGSKWv/Wv
thymus (Figure S4). The gradual decline in human B cells
and the increase in myeloid and NK cell frequencies
in BRGSK recipient bone marrow after engraftment
were compatible with our previous data in BRGS mice
(Yamauchi et al., 2013).
We analyzed subsets of human CD33+ myeloid cells re-
constituted in the injected right femur at 20–24 weeks after428 Stem Cell Reports j Vol. 7 j 425–438 j September 13, 2016transplantation. As shown in Figure 4, all myeloid lineage
cells were present in BRGS and BRGSK mice. Neutrophils,
eosinophils, basophils, and mast cells were separated by
fluorescence-activated cell sorting (FACS) as side scatter
(SSC)highCD125, SSChighCD125+, SSClowCD14CD117
CD125lowFc 3R1a+, and SSClowCD14CD117+ populations,
respectively (Figure 4A). SSClowCD11b+CD14+ mono-
cytes, SSClowCD14CD11c+CD123HLA-DR+ conven-
tional dendritic cells (cDCs), and SSClowCD14CD11c
CD123highHLA-DR+ plasmacytoid dendritic cells (pDCs)
were also evident. Figure 4B shows the morphology of
each myeloid subset purified from BRGSKWv/Wv recipients.
We then tested the expression profiles of genes related to
myeloid cell function or development. We used the Molec-
ular Signatures Database v5.1 (http://www.broadinstitute.
org/gsea/msigdb/index.jsp) to identify genes closely
related to each myeloid subset. TPSB2 and CPA3 were cho-
sen as representative genes for mast cells, RNASE2 and CLC
for eosinophils, MPO and CXCR2 for neutrophils, LYZ,
MAFB, and SLC7A7 for monocytes, CD1C and HLA-DR for
cDCs, IRF7 and TNFRSF21 for pDCs, and FLT3 for both
cDCs and pDCs. As shown in Figure 4C, each myeloid sub-
population expressed genes representative of their cellular
properties, suggesting that they developed normally in the
BRGSKWv/Wv mouse model. There were no significant dif-
ferences in the composition of myeloid cells among BRGS
and BRGSK strains (Figure 4D).
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Figure 3. Human Myeloid Reconstitution Is Enhanced in BRGSKWv/Wv Mice
Humanmyeloid and lymphoid reconstitutionwas evaluated in thebonemarrow from the right femur ofBRGS,BRGSKWv/+, andBRGSKWv/Wvmice.
(A) Representative FACS plots at 20 weeks after transplantation. Human lineage cells were analyzed within the human CD45+ population.
Numbers in FACS plots indicate the percentages of gated cells.
(B) Frequencies of human CD33+ myeloid cells, CD19+ B cells, and NKp46+ NK cells at 8–12 weeks and 20–24 weeks after transplantation.
Open and closed symbols represent females and males, respectively (n = 5–23 mice per strain). The numbers and horizontal bars indicate
mean values from four independent experiments in each strain. *p < 0.05, ***p < 0.001.
See also Figures S3 and S4.BRGSKWv/Wv Mice Reconstitute and Enhance Human
Erythropoiesis and Thrombopoiesis in the Bone
Marrow
The reconstitution of human erythroid andmegakaryocyte
lineages has been very limited by the xenogeneic trans-
plantation of human HSCs (Ishikawa et al., 2005; Takagi
et al., 2012). As shown in Figures 5A and 5B, CD235a+
erythroid cells were almost absent in the bone marrow of
BRGS and BRGSKWv/+ mice. Strikingly, BRGSKWv/Wv mice
had a high level of human erythroid reconstitution, reach-
ing an average of 42.2% and 13.7% of the total erythroid
population at 8–12 weeks and 20–24 weeks after transplan-
tation, respectively. In terms of thrombopoiesis, human
CD41+ platelets began to reconstitute in all strains at8–12 weeks after transplantation (Figure 5B, left panel),
and BRGSKWv/+ and BRGSKWv/Wv mice developed 32.7%
and 49.1% of human platelets, respectively, at 20–24 weeks
after transplantation (Figure 5B, right panel). Human
erythroid and platelet reconstitution was also present in
the non-injected left femur of BRGSKWv/Wvmice, although
the level of chimerism was low (Figure S3).
Representative FACS plots of the analysis of human
erythroid development are shown in Figure 5A. CD71
(transferrin receptor) expression on human erythroid
lineage cells gradually decreases as cells become mature
(Giarratana et al., 2005;Miharada et al., 2006). BRGSKWv/Wv
mice displayed every stage of human erythropoiesis
defined by the expression pattern of CD71 and CD235a.Stem Cell Reports j Vol. 7 j 425–438 j September 13, 2016 429
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Figure 4. Terminal Differentiation of Human Myeloid Cells in BRGSKWv/Wv Mice
(A) Representative FACS plots of human myeloid subsets within the hCD45+hCD33+ population at 20 weeks after transplantation in the
bone marrow of a BRGSKWv/Wv recipient. SSC, side scatter; FSC, forward scatter; Mast, mast cell; Mono, monocyte; Eosino, eosinophil;
Neutro, neutrophil; Baso, basophil; cDC, conventional dendritic cells; pDC, plasmacytoid dendritic cells.
(B) Morphology of each myeloid subset purified from BRGSKWv/Wv recipient bone marrow by FACS. Representative dot plots and images of
four independent experiments are shown. Scale bar, 10 mm.
(C) Relative mRNA expression levels of representative functional genes in human myeloid subsets purified from BRGSKWv/Wv recipient bone
marrow. The numbers and error bars indicate mean values and SEM, respectively (n = 4 independent experiments).
(D) Percentage of each myeloid subset within the CD33+ population at 20–24 weeks after transplantation. The data are the summary of five
BRGS, six BRGSKWv/+, and 12 BRGSKWv/Wv mice. Error bars indicate SEM from four independent experiments.CD71CD235a+ mature erythrocytes were clearly detect-
able, although the number of this population was low.
The morphology of each purified fraction is shown in
Figure 5C: CD71+CD235a cells were proerythroblasts
and basophilic erythroblasts, CD71+CD235a+ cells were
polychromatic to orthochromatic erythroblasts, and
CD71CD235a+ cells were enucleatedmature erythrocytes.
Figure 6A shows the immunohistochemical analysis
of the reconstituted human erythroid cells and megakar-
yocytes in BRGSKWv/Wv recipient bone marrow. High
numbers of CD235a+ erythroid cells were present in430 Stem Cell Reports j Vol. 7 j 425–438 j September 13, 2016BRGSKWv/Wv mice but not in BRGS mice. These erythroid
cells were functionally mature as they produced human
hemoglobin subunit a protein (Figure 6A), and expressed
human hemoglobin subunit b transcripts (Figure 6B).
BRGSKWv/Wv mice also contained a number of megakaryo-
cytes that were strongly stained with human CD41
and scattered throughout the bone marrow, which
were not found in BRGS mice. These data indicate the
enhanced functional maturation of human erythroid cells
and megakaryocytes in the bone marrow of BRGSKWv/Wv
mice.
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Figure 5. Terminal Differentiation of Human Erythropoiesis and Thrombopoiesis Is Enhanced in BRGSKWv/Wv Mice
Analysis of human erythroid and megakaryocyte reconstitution in the bone marrow from the right femur of BRGS, BRGSKWv/+, and
BRGSKWv/Wv mice.
(A) Representative FACS plots at 20 weeks after transplantation. Chimerism of erythroid cells was analyzed within the human and mouse
CD45 population. Platelets were analyzed within the Lin population, and scatter gates specific for the platelet fraction were set.
Numbers in FACS plots indicate the percentages of gated cells.
(B) Frequencies of human CD235+ erythroid cells and CD41+ platelets. Open and closed symbols represent females and males, respectively
(n = 4–23 mice per strain). The numbers and horizontal bars indicate mean values from four independent experiments in each strain.
*p < 0.05, ***p < 0.001.
(C) Morphology of CD71+CD235a proerythroblasts/basophilic erythroblasts, CD71+CD235a+ polychromatic to orthochromatic erythro-
blasts, and CD71CD235a+ enucleated mature erythrocytes in a BRGSKWv/Wv recipient. Representative images of three independent
experiments are shown. Scale bar, 10 mm.
See also Figure S3.To visualize the broad distribution of human erythroid
cells in BRGSKWv/Wv recipient bone marrow, we per-
formed three-dimensional (3D) confocal immunofluores-
cence imaging experiments by using whole-mount tissues
of the mouse sternum (Kunisaki et al., 2013) stained with
human CD71 and mouse TER119. Human hematopoiesis
was efficiently reconstituted, even in the sternal bone
marrow (Figure 6C). Interestingly, human and mouse
erythropoiesis appeared to form ‘‘erythroblastic islands’’
(Figure 6D). Either human CD71+ or mouse TER119+
erythroid cells formed colony-like structures around
the vascular network throughout the sternum, as visual-
ized by VE-cadherin/PECAM-1 staining; however, wherehuman CD71+ cells formed islands, mouse TER119+
islands did not co-exist, and vice versa (Figure 6E).
These results suggest that human erythroid reconstitution
is achieved by outcompeting host erythropoiesis for
putative ‘‘erythroid’’ niches in the bone marrow of
BRGSKWv/Wv mice.
Systemic Depletion of Macrophages Releases Human
Erythrocytes and Platelets into the Circulation of
BRGSKWv/Wv Mice
In previous human-to-mouse xenogeneic transplantation
models, circulating human erythrocytes or platelets were
not usually observed (Chen et al., 2009; Rongvaux et al.,Stem Cell Reports j Vol. 7 j 425–438 j September 13, 2016 431
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Figure 6. Immunohistochemistry and 3D Confocal Immunofluorescence Imaging of Human Megakaryo-Erythroid Lineage Cells in
BRGSKWv/Wv Mice
(A) Immunohistochemical analysis of human CD235a, hemoglobin subunit a (Hba), and CD41 expression in the femoral bone marrow of
BRGS and BRGSKWv/Wv mice (magnification: top row,3100; bottom row,3600). Representative images of four independent experiments
are shown. Scale bars: top row, 200 mm; bottom row, 20 mm.
(B) Relative mRNA expression levels of human hemoglobin subunit b (HBB) in human myeloid and CD235a+ erythroid cells purified from
BRGSKWv/Wv recipient bone marrow. The numbers and error bars indicate mean values and SEM, respectively (n = 4 independent experi-
ments). Mast, mast cell; Eosino, eosinophil; Neutro, neutrophil; Mono, monocyte.
(C–E) 3D reconstructed images of whole-mount sternal bone marrow from BRGSKWv/Wv recipients stained with human CD71 (red),
mouse TER119 (yellow), VE-cadherin (white), and PECAM-1 (white) antibodies at 20 weeks after transplantation. Representative
images from BRGSKWv/Wv recipients with high erythroid chimerism (C) and with intermediate erythroid chimerism (D) are shown. Scale
bars, 800 mm. (E) Extended images of the square area in (D). Data shown are representative of six independent experiments. Scale bar,
50 mm.2013; Takagi et al., 2012). They were also undetectable in
BRGSKWv/Wv mice (Figure 7A). We considered that
mature human blood cells might still be engulfed by
mouse macrophages, even after the introduction of
NOD-Sirpa, because hemosiderin was deposited in the
spleen of BRGSKWv/Wv mice with human hematopoietic
reconstitution (data not shown). Previous studies re-
ported that after xenotransplantation of a high dose
(1–5 3 105 cells) of human CD34+ fetal liver cells, which
have strong erythroid expansion potential (Holyoake
et al., 1999), the elimination of host macrophages by
clodronate administration accelerated the peripheral
distribution of human mature cells (Hu and Yang, 2012;
Hu et al., 2011). We therefore tested whether clodronate432 Stem Cell Reports j Vol. 7 j 425–438 j September 13, 2016treatment could induce human erythrocytes and platelets
into the circulation of BRGSKWv/Wv mice transplanted
with human CB cells. Injection of clodronate liposomes
(100–200 mL per injection) was started at 13 weeks after
transplantation, and continued for 3 weeks. Strikingly, a
statistically significant number of circulating human
CD71CD235a+ mature erythrocytes and human CD41+
platelets appeared after clodronate treatment (Figure 7B).
Our findings show that human hematopoiesis can prog-
ress up to the mature erythrocyte and platelet stages
in BRGSKWv/Wv mouse bone marrow, whereas mouse
macrophages in BRGSKWv/Wv mice might still prevent
these cells from circulating, presumably by engulfing
them in the bone marrow and/or spleen.
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Figure 7. Effect of Systemic Macrophage Depletion on the Peripheral Distribution of Human Erythrocytes and Platelets in
BRGSKWv/Wv Mice
BRGSKWv/Wv recipients at 13 weeks after transplantation were injected intraperitoneally with clodronate (n = 3) or control (n = 3) lipo-
somes for 3 weeks (200 ml for the first injection and 100 ml every 4 days thereafter). Human erythroid and megakaryocyte reconstitution
were analyzed at 16 weeks after transplantation.
(A) Representative FACS plots are shown. Chimerism of erythroid cells was analyzed within the human and mouse CD45 population.
Platelets were analyzed within the Lin population, and scatter gates specific for the platelet fraction were set. Note that all circulating
CD235a+ cells were CD71 mature erythrocytes. Numbers in FACS plots indicate the percentages of gated cells.
(B) Frequencies of human CD235+ erythrocytes and CD41+ platelets in the peripheral blood. The numbers and horizontal bars indicate mean
values from three independent experiments. *p < 0.05.DISCUSSION
Althoughmany immunodeficientmouse strains have been
developed, it has become clear that most models display
B-lymphoid dominant reconstitution after the xenogeneic
transplantation of human HSPCs (Doulatov et al., 2012;
Ito et al., 2012; Rongvaux et al., 2013; Yamauchi et al.,
2013). Genetically delivered human cytokines have greatly
improved myelomonocytic differentiation (Rathinam
et al., 2011; Rongvaux et al., 2011, 2014; Takagi et al.,
2012; Willinger et al., 2011); however, human erythroid
and megakaryocyte reconstitution is still limited (Chen
et al., 2009; Rongvaux et al., 2011; Takagi et al., 2012). In
the present study, we showed that BRGSmice homozygous
for KitWv (BRGSKWv/Wv) repopulated robust human eryth-
ropoiesis and thrombopoiesis as well as myelopoiesis.
Among the Kit mutations, KitW, the null mutant, is the
most severe type, and KitWv and KitW41, which lack the
intracellular signaling portion of KIT, are less severe (Nocka
et al., 1990). Mice homozygous for KitW are lethal, those
homozygous for KitWv are viable but sterile, and thosehomozygous for KitW41 are fertile (Nocka et al., 1990). In
addition, these phenotypes correspond to the degree of
impairment in hematopoiesis (Sharma et al., 2007). Based
on these data, we chose to introduce the KitWv mutation
into the BRGS strain, as it should provide the strongest
inhibition of KIT signaling while still preserving the viable
phenotype.
Previous studies reported that the introduction of KitW41
or KitWv mutations into BALB-RG or NSG mice could
render mouse HSCs uncompetitive to donor human
HSCs (Cosgun et al., 2014; McIntosh et al., 2015). They
also showed that human HSPCs injected at a high dose
(5 3 104 to 3 3 105 CD34+ CB cells), without irradiation
preconditioning, could outcompete mouse HSCs for
engraftment and differentiate into myeloerythroid cells.
This is probably because the introduction of loss-of-func-
tion Kitmutations might render host HSCs uncompetitive
in occupying HSC niches. The BRGSKWv/Wv mouse also
reconstituted human hematopoiesis, without irradiation,
after a high dose of human HSPC transplantation (data
not shown). However, when these mice were irradiated,Stem Cell Reports j Vol. 7 j 425–438 j September 13, 2016 433
only a small number (3.5–5 3 103 cells) of human
CD34+CD38CB cells was sufficient to achieve a high level
of human cell chimerism of erythroid and megakaryocyte
lineage cells. Thus, the introduction of homozygous KitWv
mutations into mice with severe combined immunodefi-
ciency, in combination with irradiation preconditioning,
allows the robust reconstitution of human erythropoiesis
and thrombopoiesis with terminal maturation.
Mice with Kit mutations display macrocytic anemia
(Nocka et al., 1990) and impairment of megakaryopoiesis
and myelopoiesis (Chervenick and Boggs, 1969; Ebbe
et al., 1973) as themajor hematopoietic phenotypes. These
changes might be explained by the decreased affinity be-
tween HSPCs and their niches by attenuated KIT signaling.
In this context,Kitmutationsmight help open the putative
‘‘myeloid,’’ ‘‘erythroid,’’ or ‘‘megakaryocyte’’ niches, result-
ing in the ample reconstitution of human myeloid,
erythroid, and megakaryocyte cell lineages in the bone
marrow. Indeed, robust human erythropoiesis occurred in
the sternal bone marrow of BRGSKWv/Wv mice, where hu-
man erythroid cells colonized, forming ‘‘islands’’ indepen-
dently of mouse erythroid cells. This suggested that these
cells migrated and competed for mouse ‘‘erythroid’’ niches
in the bonemarrow. However, the level of humanCD235a+
or CD41+ cell chimerism was lower than that of human
CD45+ cell chimerism, even in BRGSKWv/Wv mice. In
addition, maturation of human erythroid cells was imper-
fect, as the number of CD71CD235a+mature erythrocytes
was limited. Human erythroid reconstitution was not
improved further by injecting recombinant human eryth-
ropoietin into BRGSKWv/Wv mice (data not shown). There-
fore, some other unknown determinants, critical for the
faithful regeneration of human hematopoiesis, may still
be lacking in the bone marrow microenvironment of
BRGSKWv/Wv mice.
We did not observe circulating erythrocytes or platelets,
even in BRGSKWv/Wv mice with a very high chimerism of
human hematopoiesis. In the bone marrow, we detected
cells at every stage of human erythroid differentiation,
includingmature enucleated erythrocytes that synthesized
hemoglobin, and mature human megakaryocytes with
multiple nuclei. Of note, nearly 50% of platelets in the
bonemarrowwere of human origin. Furthermore, elimina-
tion of phagocytic cells by clodronate successfully released
a fraction of mature erythrocytes and platelets into the
circulation. Thus, the final developmental step, migration
from the bone marrow to the circulation and sustainment
in the circulation, might not yet be ‘‘humanized’’ even in
BRGSKWv/Wv mice harboring NOD-Sirpa. It is possible
that the xenogeneic activation of mouse macrophages to
engulf human cells does not depend solely on the SIRPA-
CD47 interaction, and that other unknown mechanisms
of macrophage activation against human cells exist. Clodr-434 Stem Cell Reports j Vol. 7 j 425–438 j September 13, 2016onate administration, however, was unable to deplete all
host macrophages, because a considerable number of resid-
ual macrophages were present, at least in the spleen (data
not shown). Macrophages reside throughout the body,
including around blood vessels in the bone marrow
niches (Ehninger and Trumpp, 2011). New strategies to
completely inhibit mouse macrophage activity against hu-
man cells should be developed to establish a more faithful
humanized model with circulating mature human blood
cells.
In BRGSKWv/Wvmice, the level of myeloid reconstitution
was up to 30% and 60% at 8–12 weeks and 20–24 weeks
after transplantation, respectively. These levels might be
comparable with those in MITRG mice in which four crit-
ical myeloid cytokines were humanized (Rongvaux et al.,
2014), although a direct comparison is difficult owing to
differences in dose, source, and injection methods of hu-
man HSPCs. Specifically, MITRG mice were reconstituted
with 105 human CD34+ fetal liver cells by intrahepatic in-
jection. The humanization of key cytokines should be
important for the functional maturation of myeloid cells
(Rathinam et al., 2011; Rongvaux et al., 2011, 2014; Will-
inger et al., 2011). However, the introduction of homozy-
gous KitWv mutations was sufficient for reconstituted
myeloid cells to maturate morphologically and to express
genes related to their functions. It will be of interest to
test whether the BRGSKWv/Wv mouse model can further
improve human multi-lineage reconstitution potential by
humanization of key cytokines.
In summary, we introduced the loss-of-function KitWv
mutation into the BRGSmouse strain and achieved a high-
ly efficient, long-term, and multi-lineage engraftment of
human HSCs. This line can reconstitute robust human
erythropoiesis and thrombopoiesis without exogenous
human cytokine support. The BRGSKWv/Wv mouse line is
a useful tool to help increase our understanding of the
biology of human multi-lineage hematopoiesis and a vari-
ety of malignant hematopoietic disorders.EXPERIMENTAL PROCEDURES
Mice
C57BL/6J-KitWv mice were purchased from the Jackson Laboratory.
BRGS mice were developed in our laboratory (Yamauchi et al.,
2013). The BRGSKWv/+ mouse was generated by breeding BRGS
and heterozygous C57BL/6J-KitWv mice, and the BRGSKWv/Wv
mouse line was maintained by crossing BRGSKWv/+ pairs. All mice
were bred and maintained under specific pathogen-free conditions
at the Kyushu University Animal Facility. Rag2, Il2rg, Sirpa, and Kit
genes were genotyped by direct sequencing after PCR amplification
to identify the genotype of BRGSK mice. Primer sequences are
described in our previous report (Yamauchi et al., 2013) and the
JAX website (http://jaxmice.jax.org/strain/000049.html).
Determination of the Irradiation Dose
To determine the irradiation dose for BRGSK mice, we first
evaluated the effect of the KitWv allele on radiation sensitivities.
Groups of 6- to 10-week-old heterozygous or homozygous
C57BL/6J-KitWv mice were irradiated by a 77.7-TBq (2.1 kCi)
137Cs g-irradiator with a dose rate of 70 cGy/min and monitored
for 8 weeks. As shown in Figure S1, most C57BL/6J-KitWv hetero-
zygotes receiving greater than 550 cGy irradiation died (Fig-
ure S1A), and all C57BL/6J-KitWv homozygotes irradiated with
greater than 200 cGy died within 3 weeks (Figure S1B). In xeno-
transplantation experiments, BRGSK mice were irradiated with
75% of the sublethal dose for C57BL/6J-KitWv mice. BRGSKWv/+
and BRGSKWv/Wv mice received 450 cGy and 150 cGy of irradia-
tion preconditioning, respectively.Xenogeneic Transplantation of Human HSCs into
Immunodeficient Mice
CB cells were collected during normal full-time deliveries
after obtaining informed consent in accordance with the Declara-
tion of Helsinki (provided by the Japanese Red Cross Kyushu Cord
Blood Bank). Mononuclear cells were concentrated by standard
gradient centrifugation, and CD34-enriched CB cells were ob-
tained using a Lineage Cell Depletion Kit (Miltenyi Biotec). A total
of 3.5–5 3 103 sorted LinCD34+CD38 CB cells were injected in-
trafemorally into 6- to 8-week-old BRGSK and control BRGS mice.
BRGS, BRGSKWv/+, and BRGSKWv/Wv mice were irradiated at a
sublethal dose (550, 450, and 150 cGy, respectively). After trans-
plantation, mice were given sterile water containing prophylactic
enrofloxacin (Baytril; Bayer HealthCare). Animal experiments
were conducted according to the guidelines of the Institutional
Animal Committee of Kyushu University.Flow Cytometric Analysis of Human Hematopoietic
Chimerism
At 8, 12, 16, 20, or 24 weeks after transplantation, samples
of bone marrow, spleen, thymus, and peripheral blood were
harvested from recipient mice, and single-cell suspensions
were analyzed and sorted using either FACSAria2 or FACSAria3
(BD Biosciences). After lysis of erythrocytes with Pharm Lyse
(BD Biosciences), cells were stained with monoclonal antibodies.
For the analysis of erythroid cells and platelets, untreated sam-
ples were stained and analyzed by setting scatter gates specific
for each cell fraction. FACS-purified human cells were confirmed
morphologically by May-Giemsa staining. Details about the
antibodies used are provided in Supplemental Experimental
Procedures.Immunohistochemistry and Whole-Mount Confocal
Immunofluorescence Imaging
Sectionsprepared fromparaformaldehyde-fixedparaffin-embedded
mouse femoral bone marrow tissues were immunostained with
antibodies. Sternal bones were harvested for immunofluorescence
imaging and transected with a surgical blade into two fragments
as described previously (Kunisaki et al., 2013). The fragments were
sagittally bisected to expose the bonemarrow cavity and then fixed
in 4% paraformaldehyde. Whole-mount tissues of the sterna wereblocked and permeabilized in PBS containing 20% normal goat
serum and 0.5% Triton X-100, then stained with antibodies for
2–3 days. Images were acquired using an Axio Examiner D1 micro-
scope (Zeiss) with a confocal scanner unit, CSUW1CU (Yokogawa),
and reconstructed in 3D using Image-Pro software (Media Cyber-
netics). Details about the antibodies used are provided in Supple-
mental Experimental Procedures.
Clodronate Treatment
Macrophages were depleted in vivo by intraperitoneal injection of
clodronate-encapsulated liposomes (Clophosome-A; FormuMax
Scientific). Clodronate liposomes were given at 200 mL per mouse
for the first injection and then 100 mL per mouse every 4 days for
3 weeks. Control mice were treated at the same time with empty
liposomes (Control anionic liposomes; FormuMax Scientific).
Gene-Expression Analysis
Reconstituted human CD235a+ erythroid cells and each myeloid
subpopulation within the CD33+ population were purified from
BRGSKWv/Wv mouse bone marrow, and examined for gene expres-
sion. Each target population was sorted directly to TRIzol (Life
Technologies), and the total RNA extracted was reverse transcribed
using the SuperScript III First-Strand Synthesis System (Invitro-
gen). Pre-amplification was performed using TaqMan PreAmp
Master Mix (Applied Biosystems). cDNA samples were subjected
to real-time qPCRusing the Biomark system (Fluidigm). Expression
of theGAPDH genewas used for normalization. Primers and probes
used in this assay were obtained from Applied Biosystems.
Statistical Analysis
Student’s t test was used for single comparisons, and one-way
ANOVA followed by Tukey’s HSD (honestly significant difference)
test for multiple comparisons. All statistical analyses were per-
formed using JMP software (version 11.0; SAS Institute, www.sas.
com) and p values of less than 0.05 were considered statisti-
cally significant. The Mantel-Cox log-rank test was used to obtain
survival curves.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures and four figures and can be found with this article on-
line at http://dx.doi.org/10.1016/j.stemcr.2016.07.002.
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